Fig. 2.
Pharmacokinetic model for telapristone and CDB-4453, where F is the oral bioavailability, Ka is the absorption rate constant, CL/F is telapristone oral clearance, V2/F is the apparent volume of distribution for the central compartment of telapristone, V4/F is the apparent volume of distribution for the peripheral compartment for telapristone, Q/F is the apparent intercompartmental clearance for telapristone, Fmet true is the true fraction of telapristone converted to CDB-4453, Fmet est is the true fraction of telapristone converted to CDB-4453 to distribution volume of CDB-4453 (Fmettrue/V3app), V3/F is the apparent volume of distribution for CDB-4453 (V3app), and CLM/F is the apparent clearance of CDB-4453